{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T10:51:09Z","timestamp":1791456669053,"version":"4.3.4"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hypertension is the leading modifiable risk factor for stroke and a major contributor to cognitive impairment and dementia, with its global burden increasing alongside population aging. Hypertension promotes cerebrovascular damage through endothelial dysfunction, blood\u2013brain barrier disruption, small vessel disease, and accelerated atherosclerosis, all potentially contributing to both ischemic and hemorrhagic stroke risk. These vascular alterations also contribute to neurodegenerative processes, linking hypertension\u2014particularly when present in midlife\u2014to vascular dementia and Alzheimer\u2019s disease. Effective blood pressure control (target &amp;lt;130\/80 mm Hg) remains central to primary and secondary stroke prevention and is associated with reduced risks of recurrent stroke and cognitive decline. The renin\u2013angiotensin\u2013aldosterone system plays a central role in hypertension-related cerebrovascular injury, with aldosterone excess contributing to vascular inflammation, oxidative stress, and impaired cerebral autoregulation. Resistant hypertension, often driven by aldosterone dysregulation, is associated with increased cardiovascular and neurological risk. Aldosterone synthase inhibitors such as lorundrostat and baxdrostat represent a novel therapeutic approach targeting aldosterone production. Clinical trials demonstrate significant reductions in systolic blood pressure with favorable safety profiles in patients with uncontrolled or resistant hypertension. Although direct evidence for stroke prevention is currently lacking, indirect data suggest that sustained blood pressure reduction and modulation of aldosterone-mediated vascular damage may lower cerebrovascular risk. Aldosterone synthase inhibitors may be particularly relevant in phenotype-driven, personalized treatment strategies for patients with resistant hypertension or suspected aldosterone excess. However, long-term efficacy, safety, and impact on hard outcomes such as stroke and dementia require confirmation in dedicated trials.<\/jats:p>","DOI":"10.1093\/ajh\/hpag091","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:44:43Z","timestamp":1784288683000},"page":"S57-S65","source":"Crossref","is-referenced-by-count":0,"title":["Aldosterone, the brain, and the blood pressure ceiling: a neurological case for aldosterone synthase inhibitors in resistant hypertension"],"prefix":"10.1093","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0986-6575","authenticated-orcid":false,"given":"Virginia","family":"Cancelloni","sequence":"first","affiliation":[{"name":"Stroke Unit, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia , Perugia,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2020-8891","authenticated-orcid":false,"given":"Valeria","family":"Caso","sequence":"additional","affiliation":[{"name":"Division of Neurology-Stroke Unit, Saronno Hospital, ASST Valle Olona , Saronno,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"key":"2026100806025136200_hpag091-B1"},{"key":"2026100806025136200_hpag091-B2","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1097\/HJH.0000000000000753","article-title":"Hypertension and lifetime risk of stroke","volume":"34","author":"Turin","year":"2016","journal-title":"J Hypertens"},{"key":"2026100806025136200_hpag091-B3","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s12265-017-9754-0","article-title":"Severity of hypertension correlates with risk of thromboembolic stroke","volume":"10","author":"Pang","year":"2017","journal-title":"J Cardiovasc Transl Res"},{"key":"2026100806025136200_hpag091-B4","doi-asserted-by":"publisher","first-page":"3238165","DOI":"10.1155\/2018\/3238165","article-title":"Stroke in the 21st century: a snapshot of the burden, epidemiology, and quality of life","volume":"2018","author":"Donkor","year":"2018","journal-title":"Stroke Res Treat"},{"key":"2026100806025136200_hpag091-B5","doi-asserted-by":"publisher","first-page":"995","DOI":"10.3233\/JAD-230029","article-title":"Sleep quality, metabolic function, physical activity, and neurocognition among individuals with resistant hypertension","volume":"93","author":"Smith","year":"2023","journal-title":"J Alzheimers Dis"},{"key":"2026100806025136200_hpag091-B6","doi-asserted-by":"publisher","first-page":"102278","DOI":"10.1016\/j.arr.2024.102278","article-title":"Vascular dementia: from pathobiology to emerging perspectives","volume":"96","author":"Morgan","year":"2024","journal-title":"Ageing Res Rev."},{"key":"2026100806025136200_hpag091-B7","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1161\/CIRCRESAHA.122.319951","article-title":"Post-stroke cognitive impairment and dementia","volume":"130","author":"Rost","year":"2022","journal-title":"Circ Res"},{"key":"2026100806025136200_hpag091-B8","doi-asserted-by":"publisher","first-page":"720715","DOI":"10.3389\/fnagi.2021.720715","article-title":"Vascular dementia and underlying sex differences","volume":"13","author":"Akhter","year":"2021","journal-title":"Front Aging Neurosci."},{"key":"2026100806025136200_hpag091-B9","doi-asserted-by":"publisher","first-page":"E364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke."},{"key":"2026100806025136200_hpag091-B10","doi-asserted-by":"publisher","first-page":"e461","DOI":"10.1161\/STR.0000000000000513","article-title":"2026 guideline for the early management of patients with acute ischemic stroke: a guideline from the American Heart Association\/American Stroke Association","volume":"57","author":"Prabhakaran","year":"2026","journal-title":"Stroke."},{"key":"2026100806025136200_hpag091-B11","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1161\/CIRCRESAHA.116.308398","article-title":"Stroke risk factors, genetics, and prevention","volume":"120","author":"Boehme","year":"2017","journal-title":"Circ Res."},{"key":"2026100806025136200_hpag091-B12","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1177\/0271678X18800589","article-title":"The importance of comorbidities in ischemic stroke: impact of hypertension on the cerebral circulation","volume":"38","author":"Cipolla","year":"2018","journal-title":"J Cereb Blood Flow Metab."},{"key":"2026100806025136200_hpag091-B13","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1046\/j.1440-1681.1999.03081.x","article-title":"Hypertension mechanisms causing stroke","volume":"26","author":"Johansson","year":"1999","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"2026100806025136200_hpag091-B14","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.atherosclerosis.2008.10.028","article-title":"Hypertension and cerebrovascular damage","volume":"205","author":"Veglio","year":"2009","journal-title":"Atherosclerosis."},{"key":"2026100806025136200_hpag091-B15","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1161\/CIRCRESAHA.121.319949","article-title":"Cerebral hemorrhage: pathophysiology, treatment, and future directions","volume":"130","author":"Magid-Bernstein","year":"2022","journal-title":"Circ Res"},{"key":"2026100806025136200_hpag091-B16","doi-asserted-by":"publisher","first-page":"e2333353","DOI":"10.1001\/jamanetworkopen.2023.33353","article-title":"Use of antihypertensives, blood pressure, and estimated risk of dementia in late life: an individual participant data meta-analysis","volume":"6","author":"Lennon","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026100806025136200_hpag091-B17","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13024-023-00640-5","article-title":"Pathophysiology and probable etiology of cerebral small vessel disease in vascular dementia and Alzheimer\u2019s disease","volume":"18","author":"Inoue","year":"2023","journal-title":"Mol Neurodegener."},{"key":"2026100806025136200_hpag091-B18","doi-asserted-by":"publisher","first-page":"e209715","DOI":"10.1212\/WNL.0000000000209715","article-title":"Blood pressure, antihypertensive use, and late-life Alzheimer and non-Alzheimer dementia risk: an individual participant data meta-analysis","volume":"103","author":"Lennon","year":"2024","journal-title":"Neurology."},{"key":"2026100806025136200_hpag091-B19","doi-asserted-by":"publisher","first-page":"821135","DOI":"10.3389\/fneur.2022.821135","article-title":"Hypertension and cognitive impairment: a review of mechanisms and key concepts","volume":"13","author":"Canavan","year":"2022","journal-title":"Front Neurol"},{"key":"2026100806025136200_hpag091-B20","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3233\/JAD-220846","article-title":"Regional white matter hyperintensities and Alzheimer\u2019s disease biomarkers among older adults with normal cognition and mild cognitive impairment","volume":"92","author":"Newton","year":"2023","journal-title":"J Alzheimers Dis"},{"key":"2026100806025136200_hpag091-B21","doi-asserted-by":"publisher","first-page":"I","DOI":"10.1177\/23969873221100032","article-title":"European Stroke Organisation (ESO) guideline on pharmacological interventions for long-term secondary prevention after ischaemic stroke or transient ischaemic attack","volume":"7","author":"Dawson","year":"2022","journal-title":"Eur Stroke J"},{"key":"2026100806025136200_hpag091-B22","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.1161\/STR.0000000000000475","article-title":"2024 guideline for the primary prevention of stroke: a guideline from the American Heart Association\/American Stroke Association","volume":"55","author":"Bushnell","year":"2024","journal-title":"Stroke"},{"key":"2026100806025136200_hpag091-B23","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/S0140-6736(21)00590-0","article-title":"Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis","volume":"397","author":"Adler","year":"2021","journal-title":"Lancet"},{"key":"2026100806025136200_hpag091-B24","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(01)06178-5","article-title":"Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack","volume":"358","author":"PROGRESS Collaborative Group","year":"2001","journal-title":"Lancet."},{"key":"2026100806025136200_hpag091-B25","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1177\/17474930211068671","article-title":"Triple therapy prevention of recurrent intracerebral disease events trial: rationale, design and progress","volume":"17","author":"Anderson","year":"2022","journal-title":"Int J Stroke."},{"key":"2026100806025136200_hpag091-B26","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/S0140-6736(21)00590-0","article-title":"Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis","volume":"397","author":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration","year":"2021","journal-title":"Lancet"},{"issue":"7","key":"2026100806025136200_hpag091-B27","doi-asserted-by":"publisher","first-page":"CD007858","DOI":"10.1002\/14651858.CD007858.pub230024023","article-title":"Blood pressure-lowering treatment for preventing recurrent stroke, major vascular events, and dementia in patients with a history of stroke or transient ischaemic attack","volume":"7","author":"Zonneveld","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2026100806025136200_hpag091-B28","doi-asserted-by":"publisher","first-page":"E53","DOI":"10.1161\/HYP.0000000000000084","article-title":"Resistant hypertension: detection, evaluation, and management a scientific statement from the American Heart Association","volume":"72","author":"Carey","year":"2018","journal-title":"Hypertension"},{"key":"2026100806025136200_hpag091-B29","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1097\/HJH.0000000000003151","article-title":"Lifestyle modification and cognitive function among individuals with resistant hypertension: cognitive outcomes from the TRIUMPH trial","volume":"40","author":"Smith","year":"2022","journal-title":"J Hypertens"},{"key":"2026100806025136200_hpag091-B30","doi-asserted-by":"publisher","first-page":"4980","DOI":"10.1093\/eurheartj\/ehac584","article-title":"Blood pressure lowering and prevention of dementia: an individual patient data meta-analysis","volume":"43","author":"Peters","year":"2022","journal-title":"Eur Heart J"},{"key":"2026100806025136200_hpag091-B31","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1161\/STROKEAHA.120.032054","article-title":"PRESERVE: randomized trial of intensive versus standard blood pressure control in small vessel disease","volume":"52","author":"Markus","year":"2021","journal-title":"Stroke."},{"key":"2026100806025136200_hpag091-B32","doi-asserted-by":"publisher","first-page":"1456211","DOI":"10.3389\/fendo.2024.1456211","article-title":"Aldosterone in the brain and cognition: knowns and unknowns","volume":"15","author":"Nieckarz","year":"2024","journal-title":"Front Endocrinol (Lausanne)."},{"key":"2026100806025136200_hpag091-B33","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/ajh\/hpu161","article-title":"Aldosterone, cognitive function, and cerebral hemodynamics in hypertension and antihypertensive therapy","volume":"28","author":"Hajjar","year":"2015","journal-title":"Am J Hypertens"},{"key":"2026100806025136200_hpag091-B34","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1161\/HYPERTENSIONAHA.107.095489","article-title":"Aldosterone and vascular inflammation","volume":"51","author":"Brown","year":"2008","journal-title":"Hypertension."},{"key":"2026100806025136200_hpag091-B35","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","article-title":"Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism","volume":"45","author":"Milliez","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2026100806025136200_hpag091-B36","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1001\/jama.2025.9413","article-title":"Lorundrostat in participants with uncontrolled hypertension and treatment-resistant hypertension: the Launch-HTN randomized clinical trial","volume":"334","author":"Saxena","year":"2025","journal-title":"JAMA."},{"key":"2026100806025136200_hpag091-B37","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1056\/NEJMoa2507109","article-title":"Efficacy and safety of baxdrostat in uncontrolled and resistant hypertension","volume":"393","author":"Flack","year":"2025","journal-title":"N Engl J Med."},{"key":"2026100806025136200_hpag091-B38","doi-asserted-by":"publisher","first-page":"39555","DOI":"10.31083\/RCM39555","article-title":"Efficacy and safety of aldosterone synthase inhibitors for resistant hypertension: a systematic review and meta-analysis","volume":"26","author":"Zhang","year":"2025","journal-title":"Rev Cardiovasc Med."},{"key":"2026100806025136200_hpag091-B39","doi-asserted-by":"publisher","first-page":"113259","DOI":"10.5493\/wjem.v16.i1.113259","article-title":"Renin-angiotensin system blockade attenuates brain mitochondrial dysfunction, oxidative stress, and neuroinflammation associated with hypertension, metabolic disorders, and aging","volume":"16","author":"Garc\u00eda Men\u00e9ndez","year":"2026","journal-title":"World J Exp Med"}],"container-title":["American Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/39\/Supplement_1\/S57\/71667090\/hpag091.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/39\/Supplement_1\/S57\/71667090\/hpag091.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T10:02:57Z","timestamp":1791453777000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajh\/article\/39\/Supplement_1\/S57\/8875935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":39,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2026,10,8]]},"published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ajh\/hpag091","relation":{},"ISSN":["0895-7061","1941-7225"],"issn-type":[{"value":"0895-7061","type":"print"},{"value":"1941-7225","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,10,1]]}}}